Ghasempour, Ghasem; Zamani-Garmsiri, Fahimeh; Farhad, Shaikhnia; Soleimani, Ali; Hosseini Fard, Syed Reza; Leila, Janani; Teimuri, Shohreh; Parvaz, Najmeh; Mohammadi, Payam; Najafi, Mohammad (2024). Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis. Current medicinal chemistry, 31(2), pp. 223-241. Bentham 10.2174/0929867330666230228120601
Full text not available from this repository. (Request a copy)BACKGROUND
Familial hypercholesterolemia (FH) is a prevalent and potentially fatal illness that causes a substantial elevation in low-density lipoprotein cholesterol (LDL-C).
OBJECTIVE
The aim of this study was to investigate the effects of monoclonal antibodies alirocumab and evolocumab on LDL-C and other lipid parameters, as well as their safety in familial hypercholesterolemia patients.
METHODS
A comprehensive search was done on PubMed/MEDLINE, EMBASE, Web of Science (WOS/ ISI), Scopus, ClinicalTrials (www.
CLINICALTRIALS
gov), and conferences/ congress research papers. Random effect models were used to calculate mean differences (%) and risk ratios (RRs), and confidence intervals (95%).
RESULTS
Ten studies (n=1489 patients) were included in this study. PCSK9 inhibitors decreased the levels of LDL-C by -49.59% (95%CI -55.5%, -43.67%) as compared to placebo. They also didn't alter the Treatment-Emergent Adverse Event (TEAE) and neuronal events by RR 0.92 (0.75, 1.13) and 1.31 (0.66, 2.59), respectively. PCSK9 inhibitors were effective and safe in treating patients with FH.
CONCLUSION
There was high-quality evidence showing that monoclonal antibodies (alirocumab & evolocumab) lower LDL-C (GRADE: high), lipoprotein (a) (GRADE: High), triglycerides (TG) (GRADE: High), total cholesterol (GRADE: High), non-high-density lipoprotein cholesterol (nonHDL-C) (GRADE: Moderate), and apolipoprotein B (GRADE: High), and increase the HDL-C (GRADE: High) as well as apolipoprotein A1 (GRADE: High). Comparing PCSK9 inhibitors against placebo, neither TEAE (GRADE: high) nor neuronal events (GRADE: moderate) were changed. Registration number PROSPERO-CRD42022334035.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
08 Faculty of Science > Department of Biology > Institute of Cell Biology |
UniBE Contributor: |
Teimuri, Shohreh |
Subjects: |
500 Science > 570 Life sciences; biology |
ISSN: |
0929-8673 |
Publisher: |
Bentham |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
01 Mar 2023 10:45 |
Last Modified: |
14 Oct 2023 00:11 |
Publisher DOI: |
10.2174/0929867330666230228120601 |
PubMed ID: |
36852818 |
Uncontrolled Keywords: |
Alirocumab Evolocumab Familial Hypercholesterolemia Meta-Analysis PCSK9 Systematic Review |
URI: |
https://boris.unibe.ch/id/eprint/179352 |
Actions (login required)
 |
Edit item |